A Phase 2 Study of the Dual mTOR Inhibitor MLN0128 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2016
At a glance
- Drugs Sapanisertib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 21 Nov 2016 Status changed from discontinued to active, no longer recruiting.
- 21 Nov 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Nov 2017.